Abstract:Chronic hepatitis B virus (HBV) infection remains a leading cause of hepatic inflammation and damage. The pathogenesis of chronic hepatitis B (CHB) infection is predominantly mediated by persistent intrahepatic immunopathology. With the characterization of unique anatomical and immunological structure, the liver is also deemed an immunological organ, which gives rise to massive cytokines and chemokines under pathogenesis conditions, having significant implications for the progression of HBV infection. The intrahepatic innate immune system is responsible for the formidable source of cytokines and chemokines, with the latter also derived from hepatic parenchymal cells. In addition, systemic cytokines and chemokines are disturbed along with the disease course. Since HBV is a stealth virus, persistent exposure to HBV-related antigens confers to immune exhaustion, whereby regulatory cells are recruited by intrahepatic chemokines and cytokines, including interleukin-10 and transforming growth factor β, are involved in such series of causal events. Although the considerable value of two types of available approved treatment, interferons and nucleos(t)ide analogues, effectively suppress HBV replication, neither of them is sufficient for optimal restoration of the immunological attrition state to win the battle of the functional or virological cure of CHB infection. Notably, cytokines and chemokines play a crucial role in regulating the immune response. They exert effects by directly acting on HBV or indirectly manipulating target immune cells. As such, specific cytokines and chemokines, with a potential possibility to serve as novel immunological interventions, combined with those that target the virus itself, seem to be promising prospects in curative CHB infection. Here, we systematically review the recent literature that elucidates cytokine and chemokine-mediated pathogenesis and immune exhaustion of HBV infection and their dynamics triggered by current mainstream anti-HBV therapy. The predictive value of disease progression or control and the immunotherapies target of specific major cytokines and chemokines in CHB infection will also be delineated.

Hepatitis B Virus-Induced Cirrhosis: Mechanisms, Global Variations, and Treatment Advances

Cytokines and Chemokines in HBV Infection

Progress in the Antiviral Treatment of HBV-related Cirrhosis

Advances in Hepatitis B Treatment

Acute-on-chronic Liver Failure in Chronic Hepatitis B: an Update.

Present and Future Therapies for Chronic Hepatitis B.

Virus-Related Liver Cirrhosis: Molecular Basis and Therapeutic Options

Global importance of new treatment strategies to efforts to control hepatitis B virus

Emphasizing on the Antiviral Treatment of Hepatitis B-related Cirrhosis

Global burden of hepatitis B virus: current status, missed opportunities and a call for action

Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium

Role of viral factors and antiviral therapy in liver cirrhosis due to chronic hepatitis B

Advances in treatment and prevention of hepatitis B

Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection

Hepatitis B: Model Systems and Therapeutic Approaches

Current hepatitis B treatment guidelines and future research directions

Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic

Current treatment of chronic hepatitis B: Clinical aspects and future directions

Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review

Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease